Menu
Recruiting NCT06894303

Evaluation of Remote Programming of Cochlear Implants in Routine Cochlear Implant Follow-up

Observational Cochlear Hearing Loss

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Target CI v1.5 remote programming.
Who it may be relevant to
Registry conditions: Cochlear Hearing Loss. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This is a prospective and monocentric clinical investigation, non-interventional and non-randomized. The overall goal of this clinical study is to generate additional clinical data confirming the safety and efficacy of the remote programming functionality of Target CI version 1.5 and the AB Remote Support app. Hearing outcomes are expected to be similar whether a study subject's sound processor is programmed in the traditional method in the audiologist's office or whether programming is performed via remote fitting. Therefore, the study uses a non-inferiority design to determine whether sentence recognition in noise is no worse with remote fitting than in an in-office setting.

Interventions

  • Device Target CI v1.5 remote programming
    Use of the remote programming function of Target CI v1.5 and the AB remote support application

Primary outcome measures

  • 50% SRT measured as signal to noise ratio in DB (French Matrix test in noise) [Time frame: one-month chronic use of remotely fitted sound processor]
Secondary outcome measures (1)
  • Score in the Lafon phoneme test in quiet [Time frame: one-month chronic use of remotely fitted sound processor]

Eligibility criteria

Inclusion criteria

  • Ability to provide informed consent
  • Ability to give feedback on hearing impressions
  • Aged 18 years of age or older
  • Implanted with a HiResolution Bionic Ear System (HiRes 90K or HiRes 90K Advantage or HiRes Ultra or HiRes Ultra 3D) on at least one side
  • Group 1 - Unilateral: no hearing device except contralateral routing of signals (CROS) device on the contralateral side
  • Group 2 - Bilateral: implanted on both sides
  • Group 3 - Bimodal: hearing aid on the contralateral side
  • Minimum of six months of cochlear implant experience
  • Minimum of one month experience with a Naída CI M or Sky CI M sound processor
  • Fluent in French language
  • Ability to be tested via speech perception test in noise
  • Smartphone user

Exclusion criteria

  • Clinical presentation indicative of potential implanted device malfunction
  • Unrealistic expectations regarding potential benefits, risks and limitations of the investigational device as determined by the Investigator
  • Unwillingness or inability of subject to comply with all investigational requirements as determined by the Investigator

Pregnancy and breast-feeding are not exclusion criteria.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • Groupement Hospitalier Pitié Salpêtrière — Paris

Identifiers

NCT: NCT06894303 · ABInt-24-23

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗